Author of

• 18972

  +

  P2.02 - Biology/Pathology (ID 616)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Biology/Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23199

    +

    P2.02-001 - Detection of Gene Fusions in NSCLC Using NGS Fusion Assay (ID 10033)

    09:30 - 09:30  |  Author(s): M.E. Lira
    • Abstract

    Background:
    ALK/RET/ROS and MET exon 14 skipping detection are important to guide of treatment in non-small cell lung cancer (NSCLC) patients. Next generation sequencing (NGS) platform has been implemented in the daily practice for the diagnosis. However, the validation of the NGS-based panel is still complicated and difficult.
    
    Method:
    We developed NGS-based fusion assay panel to detect 183 total fusion variants including ALK/RET/ROS as well as MET exon 14 skipping. The fusion call agreement between OCP-50 NGS assay and Nanostring was performed. The result was compared with the FISH and IHC results. This study describes the validation of the assay to define assay parameters, performance characteristics and reproducibility across laboratories.
    
    Result:
    For the 55 samples analyzed, the results are as follows;

    	ALK Fusion			ROS1 Fusion			RET Fusion			METD14
    	NGS(+)	NGS(-)	Total	NGS(+)	NGS(-)	Total	NGS(+)	NGS(-)	Total	NGS(+)	NGS(-)	Total
    NS (+)	20	0	20	6	0	6	5	0	5	0	0	0
    NS (-)	1	33	34	1	47	48	0	49	49	2	52	54
    Total	21	33	54	7	47	54	5	49	54	2	52	54

    
    
    Conclusion:
    The results of our study will be of help in learning the process of establishing, validating and applying the fusion gene detection method in NSCLCs. Furthermore, NGS based OCP-50 assay for fusion detection is more accurate and reliable method for the diagnosis.